Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial
Open Access
- 4 November 2023
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (1) , 107-116
Abstract
Optimal conditioning prior to allogeneic hematopoietic stem cell transplantation for children with non-malignant diseases is subject of ongoing research. This prospective, randomized, phase 2 trial compared safety and efficacy of busulfan with treosulfan based preparative regimens. Children with non-malignant diseases received fludarabine and either intravenous (IV) busulfan (4.8 to 3.2 mg/kg/day) or IV treosulfan (10, 12, or 14 g/m2/day). Thiotepa administration (2 × 5 mg/kg) was at the investigator’s discretion. Primary endpoint was freedom from transplantation (treatment)-related mortality (freedom from TRM), defined as death between Days -7 and +100. Overall, 101 patients (busulfan 50, treosulfan 51) with at least 12 months follow-up were analyzed. Freedom from TRM was 90.0% (95% CI: 78.2%, 96.7%) after busulfan and 100.0% (95% CI: 93.0%, 100.0%) after treosulfan. Secondary outcomes (transplantation-related mortality [12.0% versus 3.9%]) and overall survival (88.0% versus 96.1%) favored treosulfan. Graft failure was more common after treosulfan (n = 11), than after busulfan (n = 2) while all patients were rescued by second procedures except one busulfan patient. CTCAE Grade III adverse events were similar in both groups. This study confirmed treosulfan to be an excellent alternative to busulfan and can be safely used for conditioning treatment in children with non-malignant disease.Keywords
Funding Information
- Medac GmbH, Wedel, Germany
- Employed by medac
This publication has 54 references indexed in Scilit:
- Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCTEuropean Journal of Pharmaceutical Sciences, 2015
- Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter TrialTransplantation and Cellular Therapy, 2014
- Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell TransplantationTherapeutic Drug Monitoring, 2014
- Long-term follow-up of children conditioned with Treosulfan: German and Austrian experienceBone Marrow Transplantation, 2012
- Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfanBlood, 2012
- Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioningBone Marrow Transplantation, 2011
- Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trialHaematologica, 2011
- Acute graft-versus-host disease in childrenBone Marrow Transplantation, 2007
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- Final adult height of patients who received hematopoietic cell transplantation in childhoodBlood, 2005